Table 2.
Sera reacting with different HIV recombinant proteins: Comparison of the recombinant in-house Dot Blot assay with commercial western blot assay.
| Sample Group | No of Specimens reacting with the indicated HIV recombinant proteins by in-house Dot Blot or Commercial Western Blot † | |||||
|---|---|---|---|---|---|---|
| P24/gp41/gp120 | P24 and gp41/120 | P24 and gp41 and gp120 | ||||
| DBA | WBA | DBA | WBA | DBA | WBA | |
| Seronegative Subjects (180) | 4 | 6 | 0 | 1 | 0 | 0 |
| Seropositive Subjects (125) | ||||||
| AIDS Patients (32) | 30 | 28 | 32 | 32 | 32 | 32 |
| Asymptomatic HIV Infected (28) | 27 | 26 | 28 | 28 | 28 | 28 |
| Infected Intravenous drug users (48) | 41 | 40 | 48 | 43 | 48 | 45 |
| Hemophilic infected subjects (17) | 14 | 15 | 16 | 15 | 17 | 15 |
† Western Blot Assay (WBA) was performed using manufacturer criteria and in-house Dot Blot Assay (DBA) was performed using CDC Criteria. Proteins are as described in Material and Methods.